Novatio Ventures

About The Fund

Novatio Ventures is a venture capital firm dedicated to accelerating the commercialization of high-potential, high-impact life science innovations. With a focus on early-stage innovation on the cusp of preclinical proof-of-concept or validation, they provide seed funding and actively collaborate with inventors, entrepreneurs, and institutions to develop and implement commercialization strategies. They also assemble management teams and secure additional capital. Based in Toronto, Boston, and Hong Kong, Novatio targets global development of innovations from Canada, U.S., China, South Korea, and other markets they believe to be ripe for outsized value creation. Through their collective experience and global industry network, they aim to achieve early exits that generate attractive, risk-mitigated financial returns. Novatio's investment range is specifically at $380,000, which reflects their focused approach to funding. Their team brings a wealth of experience across investment, scientific research, business development, capital markets, IP, legal, and operational fields. Novatio's primary aim is to identify and invest in innovative technologies that significantly impact the diagnosis and treatment of diseases. They invest in early-stage projects and prioritize transformative therapeutics, diagnostics, devices, and drug delivery technologies with a strong rationale in markets with unmet needs. Novatio also adds value by using their fundraising, monetization, business development, and licensing expertise to help secure investments and partnerships that will fund and speed up the commercial process. They are open to ideas from research scientists and entrepreneurs and will make direct seed investments while advising on optimal fundraising strategies. They are equipped to advise on structuring new or spin-off entities and provide interim management to streamline operations, establish development strategies, and minimize time to key value inflection points or additional financing.